Dr. Douglas Loe
Leede Financial Inc.
Douglas Loe, managing director and analyst at Leede Jones Gable, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors. Loe has been recognized as one of Canada's top healthcare analysts by the StarMine Analysts Awards, based on the quality of his recommendations to institutional investors. He holds a Ph.D. in biochemistry.
Recent Articles
Analyst Says Biotech's Data Supports Advancement Into Phase III 11/19/2024
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) recently released updated Phase II data from the MAvERIC trial testing CardiolRx in recurrent pericarditis, according to a Leede Financial Inc. research note.
Opportunity Arises for Co. With Cell Pouch 11/12/2024
This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report.
Medical Co. Ready for a Transformative F2025 11/05/2024
The Leede Financial Inc. analyst also noted that while F2024 is a transition year for Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), F2025 is expected to be transformative for U.S. TULSA-PRO adoption. rates.
Biotech Shares Positive Phase I Data for Alzheimer's Treatment 10/31/2024
Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%.
Co's. Cell Pouch Performs Well in Study 09/16/2024
Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report.
Long Term Care Co.'s Target Price Raised 08/14/2024
Leede Financial Inc. recently raised the target price on Extendicare Inc. (EXE:TSX) based on FQ24 financial results.
Biopharma Co. Reports Strong FQ224 Results Driven 07/11/2024
Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX).
Analyst Encouraged by ON Gov's Decision To Sustain Fees 04/02/2024
CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note.
Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says 03/26/2024
K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note.
Recent Quotes
"SVA partner, Evotec, received a formal bid to be acquired by Halozyme."
—
Dr. Douglas Loe, Leede Financial Inc.
(11/15/24)
more >
"SVA's partnership landscape should expand."
—
Dr. Douglas Loe, Leede Financial Inc.
(11/6/24)
more >
"SVA's new board member has tech commercialization experience."
—
Dr. Douglas Loe, Leede Financial Inc.
(9/20/24)
more >
"SV's Phase 1 update is positive to the Cell Pouch's medical prospects."
—
Dr. Douglas Loe, Leede Financial Inc.
(9/12/24)
more >
"Updates on Alzheimer's by three biopharmas are pertinent to PMN."
—
Dr. Douglas Loe, Leede Jones Gable
(1/27/23)
more >
"AGN plans to initiate a Phase 2b trial of ifenprodil in chronic cough."
—
Dr. Douglas Loe, Leede Jones Gable
(1/13/23)
more >
"We expect PMN to commence formal Phase 1 testing later this year."
—
Dr. Douglas Loe, Leede Jones Gable
(1/6/23)
more >
"Data presented by peers at the CTAD conference are relevant to PMN."
—
Dr. Douglas Loe, Leede Jones Gable
(12/1/22)
more >
